260 related articles for article (PubMed ID: 21294673)
1. Hormone replacement therapy and some risk factors for breast cancer among Slovenian postmenopausal women.
Cerne JZ; Ferk P; Leskosek B; Gersak K
Climacteric; 2011 Aug; 14(4):458-63. PubMed ID: 21294673
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women.
Cerne JZ; Ferk P; Frkovic-Grazio S; Leskosek B; Gersak K
Climacteric; 2012 Feb; 15(1):68-74. PubMed ID: 22132797
[TBL] [Abstract][Full Text] [Related]
3. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
[TBL] [Abstract][Full Text] [Related]
4. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329
[TBL] [Abstract][Full Text] [Related]
5. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
Khoo SK; Chick P
Med J Aust; 1992 Jan; 156(2):124-32. PubMed ID: 1736053
[TBL] [Abstract][Full Text] [Related]
6. Estrogen therapy and risk of breast cancer in postmenopausal women: a case-control study and results of a multivariate analysis.
Lumachi F; Frigo AC; Basso U; Tombolan V; Ermani M
Menopause; 2010; 17(3):524-8. PubMed ID: 20130492
[TBL] [Abstract][Full Text] [Related]
7. Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
Krajcik RA; Borofsky ND; Massardo S; Orentreich N
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
[TBL] [Abstract][Full Text] [Related]
9. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
[TBL] [Abstract][Full Text] [Related]
10. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study.
Ramnath N; Menezes RJ; Loewen G; Dua P; Eid F; Alkhaddo J; Paganelli G; Natarajan N; Reid ME
Oncology; 2007; 73(5-6):305-10. PubMed ID: 18493157
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement treatment and breast cancer risk: an age-specific analysis.
Tavani A; Braga C; La Vecchia C; Negri E; Franceschi S
Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):11-4. PubMed ID: 8993791
[TBL] [Abstract][Full Text] [Related]
13. [Estrogen replacement therapy and breast cancer].
Bakken K; Alsaker E; Eggen AE; Lund E
Tidsskr Nor Laegeforen; 2005 Feb; 125(3):282-5. PubMed ID: 15702147
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for in situ breast cancer.
Longnecker MP; Bernstein L; Paganini-Hill A; Enger SM; Ross RK
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):961-5. PubMed ID: 8959317
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
[TBL] [Abstract][Full Text] [Related]
17. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
18. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations.
Schneider C; Jick SS; Meier CR
Climacteric; 2009 Dec; 12(6):514-24. PubMed ID: 19905903
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study.
Espié M; Mares P; de Reilhac P; Chevallier T; Daurès JP
Gynecol Endocrinol; 2006 Aug; 22(8):423-31. PubMed ID: 17012103
[TBL] [Abstract][Full Text] [Related]
20. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
